Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Neostigmine+glycopyrrolate Clear all
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

NCT03909165
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 2 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Palo Alto, California • Miami, Florida • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Sep 28, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy

NCT03111121
View directory record Official record
Conditions
Microlaryngoscopy, Rigid Bronchoscopy
Interventions
Sugammadex, neostigmine, glycopyrrolate
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 28, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)

NCT03346070
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg ABW, Sugammadex 2 mg/kg IBW, Sugammadex 4 mg/kg ABW, Sugammadex 4 mg/kg IBW, Neostigmine + Glycopyrrolate, Rocuronium or Vecuronium
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
13
States / cities
Sacramento, California • Miami, Florida • Kansas City, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 28, 2026, 5:14 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Residual Neuromuscular Blockade in Cardiac Surgery Patients

NCT03574337
View directory record Official record
Conditions
Residual Neuromuscular Blockade
Interventions
Sugammadex, neostigmine/glycopyrolate
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Sep 28, 2026, 5:14 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Phase I Clinical Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of CW002

NCT01338935
View directory record Official record
Conditions
Healthy
Interventions
CW 002
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 49 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Sep 28, 2026, 5:14 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

NMBA Reversal and Postoperative Urinary Retention

NCT06948409
View directory record Official record
Conditions
Neuromuscular Blocking Agents, Urinary Retention After Procedure, Urinary Retention Postoperative, Neuromuscular Blockade Reversal Agent, Neuromuscular Blockade, Costs, Atropine, Sugammadex, Glycopyrrolate, Neostigmine, Anesthesia
Interventions
Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
70,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 28, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Results available

Postoperative Urinary Retention in Patients After Noncardiac Surgery and Reversal of Neuromuscular Block

NCT05545280
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Neostigmine with glycopyrrolate, Sugammadex
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 28, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Results available

Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery

NCT03939923
View directory record Official record
Conditions
Surgery, Coronary Artery Disease
Interventions
Rocuronium, Neostigmine, Glycopyrrolate, Sugammadex
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 28, 2026, 5:14 PM EDT
Completed Phase 3 Interventional

Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery

NCT03513406
View directory record Official record
Conditions
Burns
Interventions
Sugammadex, Neostigmine, Glycopyrrolate
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 28, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Results available

Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery

NCT03112993
View directory record Official record
Conditions
Spine Surgery
Interventions
sugammadex, Neostigmine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Sep 28, 2026, 5:14 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery

NCT03276026
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Respiratory Conditions Due to Other External Agents
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
Virtua Health, Inc.
Other
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Mount Holly, New Jersey
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Sep 28, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Intranasal Administration of a Prokinetic for Bowel Evacuation in Persons With SCI

NCT00855283
View directory record Official record
Conditions
SCI
Interventions
IN NEO, IN NEO + IN Glycopyrrolate, IV Visit
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Sep 28, 2026, 5:14 PM EDT
Not listed Phase 1 Interventional

Use of Prokinetics During Inpatient Bowel Care for SCI Patients

NCT02370433
View directory record Official record
Conditions
Spinal Cord Injury, Neurogenic Bowel
Interventions
Intravenous Neostigmine and Glycopyrrolate, Transdermal Neostigmine and Glycopyrrolate
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 28, 2026, 5:14 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Use of High Resolution Colonic Manometry in Studying Motility

NCT02574611
View directory record Official record
Conditions
Gastrointestinal Dysfunction
Interventions
Neostigmine, Glycopyrrolate, Saline (Placebo), High Resolution Colonic Manometry
Drug · Other · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 28, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Results available

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

NCT03346057
View directory record Official record
Conditions
Reversal of Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Sugammadex 16 mg/kg, Neostigmine + Glycopyrrolate, Rocuronium, Vecuronium
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 28, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage

NCT00745095
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Neostigmine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Sep 28, 2026, 5:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Transdermal Iontophoresis of Vitamin B12 Under Three Different Skin Preparations

NCT04027959
View directory record Official record
Conditions
Macrocytic Anemia With Vitamin B12 Deficiency
Interventions
Vitamin B12
Dietary Supplement
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Sep 28, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications

NCT02861131
View directory record Official record
Conditions
Postoperative Complications, Neuromuscular Blockade
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
70 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 28, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

NCT03351608
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 28, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex To IMprove Bowel Function

NCT04546672
View directory record Official record
Conditions
Bowel Dysfunction, Postoperative Complications, Neuromuscular Blockade
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 28, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Neuromuscular Blockade in Patients With Severe Renal Impairment

NCT03904550
View directory record Official record
Conditions
Neuromuscular Blockade, Renal Impairment
Interventions
Cisatracurium + Neostigmine, Rocuronium + Sugammadex
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 28, 2026, 5:14 PM EDT
Completed Phase 4 Interventional

Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery

NCT05887375
View directory record Official record
Conditions
Spine Surgery, Reversal of Neuromuscular Blockade, Urinary Retention Postoperative
Interventions
Sugammadex, Neostigmine, Glycopyrrolate, Rocuronium
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 28, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Results available

Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection

NCT06112353
View directory record Official record
Conditions
Intestinal Disease
Interventions
Neostigmine Injectable Solution, Sugammadex injection
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 28, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients

NCT03168308
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex, Neostigmine w/ Glycopyrrolate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 28, 2026, 5:14 PM EDT